veliparib,pembrolizumab
merck,abbvie
[]
nrg-gi002 with highlighting higher rates of young patients being diagnosed with rectal cancer. study platform allow for study of tnt plus new agents including veliparib and pembrolizumab. short term outcomes did not differ but 3yr os improved with pembro + tnt. #gi23 
GI Oncologist at @IUCancerCenter. @uw_hemeoncpc and @UChicagomed alum. Tweets are my own.